Ambrx Biopharma
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Ambrx Biopharma's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 1% to $7,402,000. Profit margin reached -1054%. Total operating expenses were $74,143,000.
Profit Margin
| 2019 | 10.31M | -22.31M | -216.4% |
|---|---|---|---|
| 2020 | 13.67M | -17.83M | -130.49% |
| 2021 | 7.45M | -68.28M | -916% |
| 2022 | 7.40M | -77.99M | -1053.72% |
AMAM Income Statement (2019 – 2022)
| 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
Revenue | ||||
Revenue | 7.40M | 7.45M | 13.67M | 10.31M |
Cost of revenue | 0 | 0 | 0 | 0 |
Gross profit | 7.40M | 7.45M | 13.67M | 10.31M |
Operating exp. | ||||
Research and development | 53.30M | 54.80M | 20.43M | 26.38M |
Selling and marketing | 2.72M | 0 | 0 | 0 |
Total operating expenses | 74.14M | 71.87M | 26.78M | 32.78M |
Operating income | -57.08M | -64.42M | -13.11M | -22.47M |
Other income (expenses), net | -18.97M | -3.86M | -4.72M | 157K |
Income before tax | -76.05M | -68.28M | -17.83M | -22.31M |
Income tax expense | 1.93M | 1K | 1K | -2K |
Net income | -77.99M | -68.28M | -17.83M | -22.31M |
Earnings per share | ||||
Basic EPS | -2.02 | -3.34 | -0.47 | -0.59 |
Diluted EPS | -2.02 | -3.34 | -0.47 | -0.59 |
| Data source | Data source |